Feb. 19 at 11:43 AM
$WVE Muscle Preservation, Tolerability and Alternative Administration Routes Define Obesity’s Drug Future
February 19, 2026 | Jennifer Smith-Parker
In the incredibly hot obesity drug space, with more than 700 clinical trials ongoing, Verdiva Bio and MitoRx leaders discuss how next-generation therapies are targeting lean muscle preservation, extended efficacy and better safety profiles to enable lifelong weight management.
The market success of the next generation of obesity drugs hinge on critical differentiators, including sustainable weight loss that spares muscle mass, a better side-effect profile and adherence improvement.
The incredible traction of the GLP-1 market in the diabetes and now the obesity market, with a
$1 trillion market opportunity, have stimulated both large pharma and biotechs to engage in obesity drug development.
…
https://www.biospace.com/drug-development/muscle-preservation-tolerability-and-alternative-administration-routes-define-obesitys-drug-future
